Project Grant R44DA048686

This Project Grant award of $399,483, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to leverage synergy between artificial intelligence (AI) and DNA-encoded library (DEL) technologies to identify novel polypharmacological therapeutics for substance use disorders (SUDs). The key objectives are to generate multivalent compounds that can simultaneously target and restore imbalances in the opioid, dopaminergic, and...

This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to utilize the awardee's DNA-encoded library (DEL) drug discovery platform to identify therapeutic compounds targeting the GPR37 receptor for the treatment of amphetamine use disorders. The $398,093 award to Jillion Therapeutics Inc., a for-profit biotechnology company, will fund a 1-year project to produce and purify the GPR37 receptor, conduct DEL...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $272,395 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the biochemical mechanisms of the G9A/GLP histone methyltransferases and their role in the development of addictive behaviors. The key objectives of this 2-year award, which runs from April 2025 to March 2027, are to: 1) identify specific...

This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...

This $671,310 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel therapeutic agents for the treatment of Stimulant Use Disorder (STUD). The awardee, Verisim Life, Inc., is leveraging its proprietary AI-driven drug discovery platform, BioiSim, to expedite the development of STUD drug candidates with favorable pharmacokinetic, pharmacodynamic, and safety profiles. The key goals of...

This three-year, $760,000 project grant from the National Institute on Drug Abuse will support the development of novel therapeutic lead compounds for stimulant use disorder. Funded under the Drug Abuse and Addiction Research Programs (CFDA 93.279), the award to West Virginia University Research Corporation will focus on chemical synthesis innovations to produce analogs of illudalic acid, a potent and irreversible inhibitor of protein tyrosine phosphatase receptor type D (PTPRD). PTPRD has...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $334,343 to Syncanica Bio, Inc. to develop and evaluate synthetic analogs of 8,9-dihydrocannabidiol (H2CBD) as potential therapeutic agents for substance use disorder (SUD). The project aims to: 1) synthesize a series of H2CBD analogs, 2) evaluate the analogs in zebrafish models of addiction and pain, and 3) conduct pharmacokinetic...

This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $423,313 to Biosymetrics Inc. to develop an AI-driven in vivo profiling platform in zebrafish for identifying potential therapeutics for alcohol use disorder (AUD). The project aims to leverage Biosymetrics' existing AI-based zebrafish screening capabilities and experimental findings on AUD to create a commercial platform for accelerated AUD...

This Project Grant award of $397,829 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of an AI platform to discover new therapeutics for substance use disorders (SUDs). The key products and services to be delivered include: Creating a set of curated training datasets and machine learning (ML) models to accelerate drug discovery tasks for SUDs. Identifying mechanistic targets related to the...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $304,215 to Carina Medical LLC to develop and validate a novel software platform for decentralized clinical trials (DCTs) in substance use disorder (SUD). The project aims to leverage large language models (LLMs) to automate data collection and improve efficiency and accuracy for SUD DCTs. Key objectives include developing the software...